EGFR and non-small cell lung carcinoma: It was theorised that adding pemetrexed and carboplatin chemotherapy to an oral tyrosine kinase inhibitor may improve outcomes in EGFR-mutant advanced non-small-cell lung cancer (NSCLC).This was a phase III randomized trial in patients with advanced NSCLC harboring an EGFR-sensitizing mutation and a performance status of 0 to 2 who were planned to receive first-line palliative therapy.Between 2016 and 2018, 712 patients were screened, 362 patients screen failed and 350 patients were randomly assigned to Gef (n = 176) and Gef+C (n = 174).